Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma - Wikidata - awgldk - TriplyDB

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

http://www.wikidata.org/entity/Q34621127

about

Patient-derived tumour xenografts as models for oncology drug development Novel drugs that target the metabolic reprogramming in renal cell cancer Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance Potential of Induced Metabolic Bioluminescence Imaging to Uncover Metabolic Effects of Antiangiogenic Therapy in Tumors Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization G protein-coupled receptors as oncogenic signals in glioma: emerging therapeutic avenues Twisted tango: brain tumor neurovascular interactions Is cancer a metabolic disease?In vivo models of primary brain tumors: pitfalls and perspectives.On the origin of cancer metastasis Emerging therapeutic biomarkers in endometrial cancer Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Molecular biology of gliomas: present and future challenges Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma Metabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentiality c-Src and neural Wiskott-Aldrich syndrome protein (N-WASP) promote low oxygen-induced accelerated brain invasion by gliomas Targeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanoma Nitric oxide-driven hypoxia initiates synovial angiogenesis, hyperplasia and inflammatory lesions in mice Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2 Semapimod sensitizes glioblastoma tumors to ionizing radiation by targeting microglia Metabolic impact of anti-angiogenic agents on U87 glioma cells Phosphorescence monitoring of hypoxic microenvironment in solid-tumors to evaluate chemotherapeutic effects using the hypoxia-sensitive iridium (III) coordination compound Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma Vascular endothelial growth factor participates in modulating the C6 glioma-induced migration of rat bone marrow-derived mesenchymal stem cells and upregulates their vascular cell adhesion molecule-1 expression Endothelial cell heterogeneity Cyclin G2 promotes hypoxia-driven local invasion of glioblastoma by orchestrating cytoskeletal dynamics.Opportunities and challenges for successful use of bevacizumab in pediatrics.Angiogenic inhibition in high-grade gliomas: past, present and future.Normalization of the vasculature for treatment of cancer and other diseases.Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging data Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.Bifunctional chelates optimized for molecular MRI Glioblastoma cell-secreted interleukin-8 induces brain endothelial cell permeability via CXCR2 Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma.Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients CXCL12 modulation of CXCR4 and CXCR7 activity in human glioblastoma stem-like cells and regulation of the tumor microenvironment.

P2860

Q24604068-26A4DEDB-9CA1-4DB5-9463-C648C44C64C6 Q26740187-E8A09DEF-DD80-45AD-9719-08014B88EE00 Q26746067-1FDA58EF-BB20-454D-973D-ADF1067AD250 Q26765869-C49AED5F-A755-4FC1-A37E-4385274AEAB6 Q26766351-D6F657D1-A3DA-40E3-AFCB-DE2CCBD89658 Q26781833-96BC5687-683F-4928-A4C8-7CDF61FE05BB Q26825769-9C770012-C707-43BF-9BB2-C9D0E3C570D5 Q26849613-E9FB5C68-1390-46C0-9D36-6FFE9FE3F387 Q26852241-B446E2D7-6810-429C-B4B0-CB70632C9C45 Q26862847-6F6A7A94-FB78-43A2-B224-61BF6E15E880 Q26865675-3A454974-5140-414D-9D06-CEBAE4D258FE Q26865904-91CB7BA4-4494-4E05-A374-AFA3DBC3C0F6 Q26991991-5D3967A9-8C15-4705-B9F4-C4A617BDC739 Q27001295-8E2DEE78-3B10-4135-AED9-6389EC13AC0B Q27011423-8E00D389-9ED3-4C89-92DB-5D4CF936DBA3 Q27021470-683E7712-37B5-450E-93DC-0A542A215332 Q27025007-F0E0792C-082F-4DA8-A72C-BDA28B254582 Q27305310-071057D5-81FF-4663-95C2-15D2742BF824 Q27326700-4687381A-4243-4DAB-BDEE-DED044D640A5 Q28482073-4A311AF1-76D2-48C1-93F4-BFF0B851ADBD Q28487568-A2D369A7-3425-4439-8C94-44AB2B74C83A Q28538650-41853241-1E7C-43CE-9470-1EACDF48FD6D Q28539644-BE7E8D77-71A2-47D5-95B7-C2A7AFB50922 Q28544651-27CE177D-3D3A-4ACA-819B-4657623570DD Q28546923-B1FA58AB-0738-4296-AA96-47B5870B2FCC Q28567903-491B22BB-5026-4601-9015-139CFE3B1EF6 Q28740296-DB7557F6-0F93-44FE-BAB0-5E76B63AFF26 Q30009513-634B1447-DCFC-4AC5-A53E-698858A9BFB6 Q30454883-3177F9A2-86AD-40B2-A9E3-EDEBC09DAB02 Q30455596-47B168B8-DC5B-4A9C-AC5B-F0F3A6FA25F1 Q30471456-FE1AEC6E-AE85-44B4-9EE3-5FEDECCEA1C9 Q30541574-1DBF6262-1B53-4F16-8889-BD71CD9765C8 Q30564565-69D58A74-81A0-41EB-AD00-BD9BCDA967BF Q30607148-A9239284-8B65-45C1-8A79-95E731DBA96E Q30744946-6D46508A-FF9A-4B6E-BCB8-5A01B33940EC Q30831437-1AD279FE-0410-444C-9E79-C9F4E6E0179A Q31101680-143CB3A0-B4AA-460B-98A0-96345C69D60D Q33397569-EF6077B5-CF03-4039-9519-49D383205426 Q33576750-9EF82FB0-FEC5-4461-839B-1CD73FA3CF03 Q33677057-BC4BE749-153C-4EEA-BDCE-C45FEF17E6D2

P2860

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

http://www.wikidata.org/entity/Q34621127

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@ast

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@en

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@nl

type

label

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@ast

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@en

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@nl

prefLabel

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@ast

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@en

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@nl

P1433

Q34621127-00BDF44B-A15E-49EE-AD26-393D6C393C59

P1476

Q34621127-CCB5E1A4-A972-4B1E-B1CF-10C4D1FF9BBC

P2093

Q34621127-042E2592-8825-49B9-8380-99FE15F4A7A0

Q34621127-09C4F77D-AF2F-418F-9705-5C3D133148FA

Q34621127-55D27EF7-4988-4AE8-9517-F71B414D6BDA

Q34621127-71E363C3-5992-4436-BF5B-21DCB260E4D8

Q34621127-7405C28D-893E-48F2-8D0C-4E73A9A93295

Q34621127-7D964046-E621-43AD-8842-635BE41478B5

Q34621127-7EAADE63-21BF-4D72-923D-B016F5D0D2DC

Q34621127-7F958F56-1B61-4FAA-A8A1-0BF3321D42E1

Q34621127-A86847C4-51A2-4286-9423-A18D6BF31699

Q34621127-B931844F-66AF-4CDB-B799-53B775360D1A

P2860

Q34621127-0A0B12B7-BCA9-42C3-8A58-1B03DC3FC4C0

Q34621127-0E49BE09-2F66-4848-9F5C-97537D82576B

Q34621127-0FCBA7C3-EA14-4B92-91A4-7B480965EAA8

Q34621127-11026AA1-25B8-4A57-998A-6D2F6A01FB98

Q34621127-12348341-B162-4156-B6BA-E17FB9D82B5B

Q34621127-129428D9-06B7-4194-9A90-6B1D558B7EBB

Q34621127-12ACAD22-A7E9-4C2B-9E70-BECDB49EFF5A

Q34621127-1B9B1480-6075-45CA-BA13-ACEEE98B115A

Q34621127-1CAD6482-62E6-474D-94CC-849AA6984A9F

Q34621127-2DF5939B-2FD8-4295-A304-A01C0A114D6E

P304

Q34621127-15486B78-FC8C-4602-9316-9EDDB1CA37CF

P31

Q34621127-ACF8A186-517E-47D4-8413-25CF34B9B0F6

P356

Q34621127-221EA327-D1FB-42FC-AC27-FD273B5B0881

P407

Q34621127-93F63763-9692-4214-A388-B4560D639A5C

P433

Q34621127-92DC6AA6-D56B-4B3C-91B8-0791DB2934F7

P478

Q34621127-AC46DED3-2954-444E-8925-14708CCCA69D

P50

Q34621127-174D5B7F-3B3D-4084-B185-197900CFA707

Q34621127-1ED114D4-F6F9-4605-B610-71C2675D532B

Q34621127-7D2FCD8B-AA3C-40B1-81EA-0BD89C89120F

Q34621127-CC4B2770-1A32-4A7E-8DAD-D091D06A38AD

P577

Q34621127-505E79A2-01B0-4D82-AA0E-378EFFC8A8F2

P5875

Q34621127-6EDCD06C-464D-486D-A99A-17C29552A3BD

P698

Q34621127-68A57032-316E-45CD-AF88-53B3CBF12A66

P932

Q34621127-FA1CFC0D-1DD4-4D03-B015-B12C5F7CDA38

P356

PNAS.1014480108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Anti-VEGF treatment reduces bl ...... cell invasion in glioblastoma

@en

P2093

Anaïs Oudin

http://www.w3.org/2001/XMLSchema#string

Cecilie Brekke Rygh

http://www.w3.org/2001/XMLSchema#string

Daniel Stieber

http://www.w3.org/2001/XMLSchema#string

Fred Fack

http://www.w3.org/2001/XMLSchema#string

Frits Thorsen

http://www.w3.org/2001/XMLSchema#string

Hrvoje Miletic

http://www.w3.org/2001/XMLSchema#string

Ingrid Moen

http://www.w3.org/2001/XMLSchema#string

Jian Wang

http://www.w3.org/2001/XMLSchema#string

Linda Stuhr

http://www.w3.org/2001/XMLSchema#string

Mikael Johansson

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer

Metabolic modulation of glioblastoma with dichloroacetate

Why do cancers have high aerobic glycolysis?

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Tumor cell metabolism: cancer's Achilles' heel

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

P304

3749-3754

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1014480108

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

Simone P Niclou

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836214

http://www.w3.org/2001/XMLSchema#string

P698

21321221

http://www.w3.org/2001/XMLSchema#string

P932

3048093

http://www.w3.org/2001/XMLSchema#string